U.S. Markets closed

Synairgen plc (SNG.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
220.00+14.00 (+6.80%)
At close: 4:35PM BST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close206.00
Open208.50
Bid216.00 x 0
Ask222.00 x 0
Day's Range203.98 - 223.00
52 Week Range5.50 - 231.21
Volume677,371
Avg. Volume2,983,805
Market Cap328.753M
Beta (5Y Monthly)-2.93
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Do Insiders Own Lots Of Shares In Synairgen plc (LON:SNG)?
    Simply Wall St.

    Do Insiders Own Lots Of Shares In Synairgen plc (LON:SNG)?

    If you want to know who really controls Synairgen plc (LON:SNG), then you'll have to look at the makeup of its share...

  • Is This Dark-Horse Coronavirus Stock a Threat to Gilead Sciences?
    Motley Fool

    Is This Dark-Horse Coronavirus Stock a Threat to Gilead Sciences?

    Synairgen's (LSE: SNG) stock skyrocketed on Monday amid news that the largely unknown British respiratory therapeutics company had demonstrated in a phase 2 clinical trial that its inhalable drug SNG001 reduced the chances of coronavirus patients needing a ventilator by a stunning 79%. While the results are still preliminary and need robust third-party confirmation, investors are already curious about whether SNG001 poses a threat to established competitors in the coronavirus therapeutics space, like Gilead Sciences (NASDAQ: GILD) and its antiviral drug remdesivir. In a nutshell, there's a lot to be hopeful about when it comes to Synairgen's new therapy, but that doesn't mean you should rush to sell your Gilead shares.

  • Yahoo Finance Video

    AstraZeneca and Oxford's COVID-19 vaccine brings positive results in early-stage human trials

    AstraZeneca and Oxford University's COVID-19 vaccine showed positive results in early stages of human trials. Yahoo Finance's Anjalee Khemlani joins the On the Move panel to discuss.